Complimentary Commercial Content
Data collected over the first year of CPMA availability shows improvements in survival rates for puppies battling the deadly virus, enhanced operational efficiency and high satisfaction within veterinary clinics.
Our recent real-world data shows that the Canine Parvovirus Monoclonal Antibody is giving puppies and veterinary clinic staff a new lease on life,” – Jennifer Miller, DVM
Source: PR Newswire, October 15, 2024. Link.